I
INmune Bio Inc. (INMB)
NCM – Real Time Price. Currency in USD
1.39
+0.04 (2.96%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.39
+0.04 (2.96%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 4.24 | 6.05 | 10 | |
| Quick ratio | 4.24 | 5.63 | 10 | |
| Debt to Equity | 0.08 | 0.30 | 9.0 | |
| Debt to Assets | 0.06 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 374K | 155K | 14K | 50K | N/A |
| Gross Profit | N/A | N/A | N/A | -34K | -136K |
| Operating Income | -26M | -30M | -43M | -31M | -27M |
| Net Income | -27M | -30M | -42M | -46M | -42M |
| EBITDA | -26M | -30M | -43M | -31M | -27M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 82.38 | 5.5 |
| Next quarter | N/A | 26.04 | 5.5 |
| Current year | -100 | 62.9 | 5.5 |
| Next year | N/A | -3.86 | 1.0 |
| Weighted average score | 4.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -2.71 | -1.09 | -10.23 | 3.3 |
| Y/Y | -99.99 | 44.48 | 53.49 | 50.13 | 7.8 |
| 3y average | 35.88 | -19.75 | -8.11 | -34.02 | 3.3 |
| 5y average | 354.48 | -39.99 | -18.26 | -60.06 | 3.3 |
| Weighted average score | 4.4 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $21.4M significantly exceed its total debt $1.5M, ensuring strong financial flexibility
Total current assets $22.8M exceed Total current liabilities $5.4M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$3.4M limits the company's ability to reinvest or pay down debt